CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

Study of DONQ52 in Active Celiac Disease

NCT07239336 · Phase 2 · Recruiting

PHASEPhase 2

STATUSRecruiting

ENROLLMENT92

EST. COMPLETION2027-06-15

Conditions

Celiac Disease

Interventions

Placebo DONQ52Simulated Inadvertent Gluten Exposure (SIGE) capsuleDONQ52

Study details

SPONSORChugai Pharmaceutical

START DATE2025-12-16

Related company profiles

Chugai Pharmaceutical

4519.T

Primary source

ClinicalTrials.gov record NCT07239336 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT07239336
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record